Nasonex® Nasal Suspension 50 μg Long-term Designated Drug Use Investigation (Study P05876)

Organon and Co3,806 enrolled

Overview

The investigation will be conducted to define safety and efficacy under the conditions of post-marketing use of this drug in subjects with allergic rhinitis. Post-marketing surveys are not considered applicable clinical trials and thus the results of this survey will not be posted at its conclusion. The results will be submitted to public health officials as required by applicable national and international laws.

Study Type

OBSERVATIONAL

Enrollment

3,806

Conditions

Allergic Rhinitis

Interventions

mometasone furoateDRUG

Metered-dose spray type suspension containing 50 μg mometasone furoate per spray. 2 sprays per nostril twice daily (total daily dose 200 μg) Duration: up to 6 months

Eligibility

Sex: ALL

Medical Language ↔ Plain English

Inclusion Criteria: * Patients who are treated with Nasonex for perennial or seasonal allergic rhinitis. Exclusion Criteria: * Patients with an infection for which there is no effective antimicrobial drug or systemic fungal infection \[symptoms may exacerbate\] * Patients with a history of hypersensitivity to any ingredient of this drug

Outcomes

Primary Outcomes

Estimate the incidence of Adverse Drug Reactions (ADRs)

Time frame: After 6 months of observation

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.